Srivichaivejvivat Valuation
Is VIH-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VIH-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VIH-R (THB9.35) is trading above our estimate of fair value (THB4.94)
Significantly Below Fair Value: VIH-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIH-R?
Key metric: As VIH-R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is VIH-R's PE Ratio? | |
|---|---|
| PE Ratio | 16.7x |
| Earnings | ฿341.75m |
| Market Cap | ฿5.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 7.9x |
| PEG Ratio | 4.6x |
Price to Earnings Ratio vs Peers
How does VIH-R's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.9x | ||
RJH Rajthanee Hospital | 12.3x | 0.6% | ฿6.7b |
TNH Thai Nakarin Hospital | 15.1x | n/a | ฿6.6b |
EKH Ekachai Medical Care | 15.9x | 2.1% | ฿5.1b |
PHG Patrangsit Healthcare Group | 16.3x | 11.6% | ฿4.8b |
VIH-R Srivichaivejvivat | 16.7x | 3.6% | ฿5.7b |
Price-To-Earnings vs Peers: VIH-R is expensive based on its Price-To-Earnings Ratio (16.7x) compared to the peer average (14.9x).
Price to Earnings Ratio vs Industry
How does VIH-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: VIH-R is good value based on its Price-To-Earnings Ratio (16.7x) compared to the TH Healthcare industry average (22x).
Price to Earnings Ratio vs Fair Ratio
What is VIH-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.7x |
| Fair PE Ratio | 18x |
Price-To-Earnings vs Fair Ratio: VIH-R is good value based on its Price-To-Earnings Ratio (16.7x) compared to the estimated Fair Price-To-Earnings Ratio (18x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.